Guggenheim raises Regeneron stock price target to $815 on strong Dupixent sales

Regeneron Pharmaceuticals (REGN) significantly surpassed Q2 expectations, reporting EPS of $12.89 (a 51.65% increase) and revenue of $3.68 billion, primarily driven by robust Dupixent sales and resilient performance from its Eylea franchise. This strong financial showing prompted multiple analyst firms, including Guggenheim, Bernstein, RBC Capital, and BMO Capital, to raise their price targets. While the company anticipates continued erosion for Eylea 2mg and faces a PDUFA delay for Eylea HD due to site inspection issues, management indicated a strategic shift towards considering differentiated later-stage business development opportunities.

Analysis

Regeneron Pharmaceuticals (REGN) delivered a robust second quarter for 2025, significantly outperforming market expectations with an EPS of $12.89, a 51.65% increase that far exceeded the $8.50 consensus. This performance was primarily fueled by stronger-than-anticipated sales from its blockbuster drug Dupixent, which is gaining momentum from recent launches in new indications, and the continued growth of Libtayo, now a product generating over $1 billion in annual sales with a 25% year-over-year increase. The critical Eylea franchise demonstrated resilience despite competitive pressures; while the legacy Eylea 2mg formulation saw a 10% quarter-over-quarter unit decline, the newer Eylea HD experienced a 16% QoQ increase in demand. However, the company faces a key regulatory headwind with the announced delay of the August PDUFA date for Eylea HD due to site inspection issues. In a notable strategic development, management signaled an openness to pursuing later-stage business development opportunities, a shift from its historical focus on early-stage assets. This strong financial report has led to a wave of positive analyst revisions, with firms like Guggenheim, Bernstein, and RBC Capital raising their price targets, reflecting confidence in the company's core growth drivers despite the near-term regulatory uncertainty.

Key Decisions for Investors

• Investors should weigh the company's strong fundamental performance and significant earnings beat against the near-term regulatory risk associated with the Eylea HD PDUFA delay.
• Monitor the demand trajectory for Eylea HD versus the guided 10% QoQ erosion of Eylea 2mg, as this internal transition is critical for sustaining the franchise's value.
• The articulated shift in business development strategy towards later-stage assets presents a potential future catalyst; any M&A or licensing announcements should be evaluated as a new vector for growth.
• Given the substantial beat and positive analyst revisions, current valuations with a moderate P/E of 13.6x may still present an attractive entry point, assuming the regulatory issues are resolved favorably.